Drug Profile
Research programme: tumour metabolism and microenvironment modulators - Aravive Biologics
Alternative Names: 1-series; 3-series; 5-series; 7-series; M-series; STF-31Latest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator Auckland Cancer Society Research Centre; Stanford University School of Medicine
- Developer Aravive Biologics; Auckland Cancer Society Research Centre; Stanford University School of Medicine
- Class Small molecules
- Mechanism of Action Glucose transporter type 1 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer; Ovarian cancer
Most Recent Events
- 15 Oct 2018 Aravive Biologics and Versartis merged to form Aravive
- 16 Jul 2016 No recent reports of development identified for preclinical development in Cancer in New Zealand
- 16 Jul 2016 No recent reports of development identified for preclinical development in Cancer in USA